BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Veselinović T, Neuner I. Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia. CNS Drugs 2022. [PMID: 35831706 DOI: 10.1007/s40263-022-00935-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu H, Huang Z, Zhang X, He Y, Gu S, Mo D, Wang S, Yuan Z, Huang Y, Zhong Q, Zhou R, Wu K, Zou F, Wu X. Association between lipid metabolism and cognitive function in patients with schizophrenia. Front Psychiatry 2022;13:1013698. [PMID: 36506447 DOI: 10.3389/fpsyt.2022.1013698] [Reference Citation Analysis]
2 Wang Y, Meng W, Liu Z, An Q, Hu X. Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention. Front Cell Neurosci 2022;16. [DOI: 10.3389/fncel.2022.1046692] [Reference Citation Analysis]
3 Maroney M. Management of cognitive and negative symptoms in schizophrenia. Mental Health Clinician 2022;12:282-299. [DOI: 10.9740/mhc.2022.10.282] [Reference Citation Analysis]
4 Lai CC, Baskaran R, Tsao CY, Tuan LH, Siow PF, Palani M, Lee LJ, Liu CM, Hwu HG, Lee LJ. Chronic N-Acetylcysteine Treatment Prevents Amphetamine-Induced Hyperactivity in Heterozygous Disc1 Mutant Mice, a Putative Prodromal Schizophrenia Animal Model. Int J Mol Sci 2022;23:9419. [PMID: 36012679 DOI: 10.3390/ijms23169419] [Reference Citation Analysis]